San Francisco, CA, United States of America

Adam P Arkin

This inventor holds 4 USPTO granted patents and 4 published patent applications and 1 EPO patent. Top assignee: University of California. Active years: 2017-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Adam P Arkin. Retrieved from https://idiyas.com/inventor/adam-p-arkin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 4 

% Patents Active = 75.0

 

Average Co-Inventor Count = 3.0

ph-index = 2

Forward Citations = 12(Granted Patents)


Company Filing History:


Years Active: 2017-2024

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovative Journey of Adam P Arkin

Introduction: Adam P Arkin is a renowned inventor based in San Francisco, CA, known for his groundbreaking contributions to the field of biotechnology and synthetic biology.

Latest Patents: Adam P Arkin holds several patents related to genetic engineering, bioinformatics, and microbial systems, showcasing his expertise in developing cutting-edge technologies.

Career Highlights: With a distinguished career spanning over two decades, Adam P Arkin has held key positions at prestigious research institutions and universities, leading pioneering research projects in the field of synthetic biology.

Collaborations: Throughout his career, Adam P Arkin has collaborated with leading scientists, engineers, and biotech companies to push the boundaries of innovation in genetic engineering and biological systems.

Conclusion: Adam P Arkin's passion for innovation and his relentless pursuit of scientific excellence have solidified his reputation as a trailblazer in the field of biotechnology, inspiring the next generation of inventors and researchers.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…